News
BCHMF
91.23
NaN%
--
Bachem price target raised to CHF 90 from CHF 85 at JPMorgan
TipRanks · 4d ago
Bachem Holding AG (0QND) Gets a Hold from Barclays
TipRanks · 6d ago
Jefferies Sticks to Their Sell Rating for Bachem Holding AG (0QND)
TipRanks · 08/04 14:09
RBC Capital Remains a Buy on Bachem Holding AG (0QND)
TipRanks · 08/03 06:35
Bachem Holding AG reports 1H results
Seeking Alpha · 07/30 15:39
Bachem boosts sales, ramps up capacity for peptide and oligonucleotide growth
TipRanks · 07/30 05:03
Bachem Confirms Growth and Expects a Strong Second Half 2026
Newsfile · 07/30 04:56
Bachem to Invest Over CHF 500 Million in New Sisslerfeld Peptide Plant
TipRanks · 07/21 05:02
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Newsfile · 07/21 04:40
Jefferies Reaffirms Their Sell Rating on Bachem Holding AG (0QND)
TipRanks · 07/16 12:25
Bachem Holding AG Announces Capital Markets Day 2026
Newsfile · 06/12 15:47
Bachem Plans Hybrid Capital Markets Day in Zurich for 2026
TipRanks · 06/12 13:05
RBC Capital Reaffirms Their Buy Rating on Bachem Holding AG (0QND)
TipRanks · 06/10 06:37
Bachem Holding AG (0QND) Receives a Hold from Barclays
TipRanks · 06/09 06:55
UBS Sticks to Their Buy Rating for Bachem Holding AG (0QND)
TipRanks · 06/08 08:36
Bachem CEO Assumes Dual Role as CCO Departs
TipRanks · 05/05 05:32
Bachem Announces Changes to the Corporate Executive Committee
Newsfile · 05/05 05:08
Bachem AGM Backs Board Proposals and Confirms CHF 0.90 Dividend
TipRanks · 04/29 16:35
Bachem Annual General Meeting 2026
Newsfile · 04/29 16:09
Bachem Secures Financing of Strategic Growth Initiatives
Newsfile · 04/27 05:03
More
Webull provides a variety of real-time BCHMF stock news. You can receive the latest news about Bachem Hol through multiple platforms. This information may help you make smarter investment decisions.
About BCHMF
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.